NUMERO: #20240738

Título: EXPLORING TROP2 EXPRESSION AS A POTENTIAL THERAPEUTIC TARGET IN ADENOID CYSTIC CARCINOMA OF THE SALIVARY GLANDS

Nome do Apresentador: Juliana Mota SIQUEIRA

Categoria do Trabalho: Painel de pesquisa científica (PPC)

Área Temática: Patologia Oral

Resumo: Adenoid cystic carcinoma (ACC) is a prevalent salivary gland carcinoma characterized by high rates of recurrence and distant metastasis, with no established systemic therapy. ACC can be subdivided into two types based on clinical and molecular characteristics: ACC-I (aggressive, solid histology, p63 negative) and ACC-II (indolent, tubular or cribriform histology, p63 positive). TROP2 is a transmembrane glycoprotein implicated in the development of various tumors. Sacituzumab govitecan (SG), an anti-TROP2 drug, has shown effectiveness in treating metastatic triple-negative breast cancer.

Objective: To evaluate TROP2 expression and its potential as a therapeutic target for ACC.

Methods: Immunohistochemistry (IHC) assessed TROP2 expression in 165 ACC samples, categorized by histological pattern. Additionally, RNA sequencing was conducted on 82 patient samples to investigate TROP2 and TP63 gene expression levels.

Results: TROP2 IHC expression was high in 59%, moderate in 30%, weak in 8%, and negative in 3% of ACC tumors. Non-solid ACC tumors were significantly associated with high TROP2 expression (p<0.001). Moreover, RNA sequencing demonstrated a positive correlation between TROP2 and TP63 expression, with ACC-II tumors showing higher expression levels compared to ACC-I (p<0.0001).

Conclusion: TROP2 is widely expressed in ACC, particularly in non-solid ACC-II tumors, suggesting its potential as a therapeutic target.

Autor 1:  Juliana Mota SIQUEIRA

E-mail 1:  [email protected]

Autor 2:   Yoshitsugu Mitani

E-mail 2:  [email protected]

Autor 3 :  Mario L. Marques-Piubelli

E-mail 3:  [email protected]

Autor 4:  Luana Guimaraes de Sousa

E-mail 4:  [email protected]

Autor 5:  Giovanna Lopes Carvalho

E-mail 5:  [email protected]

Autor 6:  Fabio Daumas Nunes

E-mail 6:  [email protected]

Autor 7:  Renata Ferrarotto

E-mail 7:  [email protected]